MADISON,
Wis., Oct. 2, 2023 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that the company has a
510(k) pending for an online adaptive therapy option*, Cenos™, for
its Radixact® System. The solution was unveiled, in
partnership with Limbus AI, at the 2023 ASTRO (American Society for
Radiation Oncology) Annual Meeting in San
Diego, California, October 1-4,
2023. Cenos is designed to enable medical care teams to
quickly and efficiently make adjustments, if necessary, to a
treatment plan while the patient is still on the treatment
table.
Over the course of radiation treatments the size, shape or
location of tumors may change and their proximity to organs and
other healthy tissue may shift as patients gain or lose weight.
Accuray customers are currently able to leverage real-time adaptive
therapy through the company's proprietary Synchrony®
technology and offline adaptive with PreciseART®
radiotherapy to account for some of the anatomical changes that
occur during radiation delivery. With the addition of Cenos,
Accuray customers will have the ability to perform online
adaptation of their treatment plan to account for changes that may
occur between treatment sessions. Accuray is committed to offering
the most comprehensive adaptive tool set to provide care
teams with choices and the flexibility to optimize and streamline
the workflow for each patient, helping to ensure clinical
objectives are met.
One of the most important steps in the planning process is
contouring – defining the border of the tumor and organs at risk –
yet it is extremely labor and time intensive. Automating the
contouring portion of the planning process using tools such as the
one developed by Limbus AI will make it practical for
radiotherapy clinics of all sizes to adopt online adaptive
therapy, when needed.
"We're proud of the work we're doing with Limbus and our
achievements to date. The goal of Cenos is to provide our customers
with a comprehensive and efficient approach to adaptive
radiotherapy that includes a solution for making online adaptive
therapy feasible for any interested Radixact customer," said
Suzanne Winter, President and CEO of
Accuray. "We are committed to continuing to evolve our radiation
delivery systems to facilitate more personalized care for more
cancer patients. Approximately 50% of all cancer patients will need
treatment with radiotherapy[1], making it critical that we do
everything possible to help ensure that clinicians have the tools
to optimize treatments."
"We're very happy to be partnering with Accuray," said Dr
Karl Otto, CEO of Limbus AI. "Our AI
based technology, Limbus Contour, has seen rapid adoption by over
250 clinics globally. Embedding it into the Cenos online adaptive
solution will help provide for accurate and fast contouring
essential to real-world clinical implementation of adaptive
treatment."
Additional Accuray Highlights at the ASTRO meeting
Include:
- Accuray Financial Services - new: The increasing use of Accuray
radiation delivery systems is a reflection of their precision and
accuracy, and enhancements introduced in the areas of image
quality, speed, versatility, and workflow efficiencies. In the U.S.
market Accuray is making it easier for customers to obtain the
company's advanced hardware and software or to keep their
technology up to date through flexible financing options.
- Alliance A+ - new: A curated support solutions portfolio
covering multiple functions including service, clinical
applications and physics, designed to augment medical care team
resources and optimize their practice.
- VitalHold™** Breast Package for the Radixact® System
– now 510(k) cleared and obtained CE mark in the EU market:
VitalHold enables deep inspiration breath hold (DIBH) treatments on
the Radixact System through a fully integrated and automated
surface-guided radiotherapy (SGRT) solution. The Radixact System
offers compromise-free capabilities to treat the full spectrum of
breast cases in as little as two minutes, leveraging both
TomoHelical™ (helical delivery) and TomoDirect™ (tangential
beams).
- CyberKnife® System: The CyberKnife S7™ System
combines speed, advanced precision, and real-time (AI)-driven
motion tracking and synchronization treatment delivery, using
Synchrony®, for all stereotactic radiosurgery (SRS) and
stereotactic body radiation therapy (SBRT) treatments.
*Cenos is 510(k) pending. The solution is not available for
sale in the USA. It is not CE
marked and availability is subject to regulatory clearance or
approval in some markets.
**VitalHold™ availability is
subject to regulatory clearance or approval in some
markets.
About Limbus AI
Limbus AI's passionate team of healthcare and technology
specialists is dedicated to improving cancer care through the
development of state-of-the-art software. Our machine
learning-based products improve efficiency and clinical workflows
in cancer radiation treatment planning. We specialize in the
creation of artificial intelligence (AI)-driven automatic
contouring algorithms performed on local hardware within the
security of the customers' own local network. These unique software
solutions enable clinicians to plan accurate treatments quicker,
with the same resources - allowing centers to meet the ever-growing
demand for radiotherapy. Limbus AI is headquartered in Regina Saskatchewan, Canada. To learn more,
visit www.limbus.ai or follow us on our social media.
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions designed to deliver radiation
treatments for even the most complex cases—while making commonly
treatable cases even easier—to meet the full spectrum of patient
needs. We are dedicated to continuous innovation in radiation
therapy for oncology, neuro-radiosurgery, and beyond, as we partner
with clinicians and administrators, empowering them to help
patients get back to their lives, faster. Accuray is headquartered
in Madison, Wisconsin, with
facilities worldwide. To learn more, visit www.accuray.com or
follow us on Facebook, LinkedIn, Twitter, and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to expectations and goals
regarding new products, services and innovations, expectations
regarding collaborations and partnerships, expectations regarding
continuing to evolve our systems and facilitating more personalized
care for cancer patients, patient experiences and patient outcomes.
These risks and uncertainties include, but are not limited to, the
effect of the current global economic environment, including in
connection to the COVID-19 pandemic, on the operations of the
company and those of its customers and suppliers; the company's
ability to achieve widespread market acceptance of its products;
the company's ability to develop new products or improve existing
products to meet customers' needs; the company's ability to
anticipate or keep pace with changes in the marketplace and the
direction of technological innovation and customer demands;
reliance on third party collaborators, partnerships, strategic
alliances and joint ventures; and such other risks identified under
the heading "Risk Factors" in the company's Annual Report on Form
10-K, filed with the Securities and Exchange Commission (the "SEC")
on September 7, 2023, and as updated
periodically with the company's other filings with the
SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contact
Beth Kaplan
Public Relations Director, Accuray
+1 (408)
789-4426
bkaplan@accuray.com
1 Atun R. et al. Lancet Oncol 2015; 16:
1153–86
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accuray-and-limbus-ai-unveil-online-adaptive-therapy-solution-for-the-radixact-system-at-american-society-for-radiation-oncology-astro-annual-meeting-301943994.html
SOURCE Accuray Incorporated